Comparative pharmacokinetics of two tablet formulations of losartan: Bioequivalence assessment

Biopharmaceutics and Drug Disposition

Volumn 26, Issue 5, 2005, Pages 205-210

  Tamimi, J J I ^a   Salem, I I ^a   Alam, S Mahmood ^b   Zaman, Q ^b   Dham, Ruwayda ^b  

^a Arab Company for Drug Industries & Medical Appliances   (Jordan)

^b Gulf Pharmaceutical Industries   (United Arab Emirates)

Author keywords

Bioequivalence; HPLC; Julphar; Losartan; Pharmacokinetics

Indexed keywords

BLOSART; CARBOXYLIC ACID; DRUG METABOLITE; LOSARTAN; LOSARTAN POTASSIUM;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET FORMULATION; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; HALF-LIFE; HUMANS; JORDAN; LOSARTAN; MALE; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 22144456382     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.448     Document Type: Article

References (19)

1. Sean CS (ed.). Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc: Denver, CO, Vol. 122 expires 12/2004.
2. Index Nominum: International Drug Directory. Edited by the Swiss Pharmaceutical Society © 2000. Medpharm Scientific Publishers: Stuttgart, Germany; Micromedex, Inc: Denver, CO, Vol. 122 expires 12/2004.
3. Rush JE, Rajfer SI. Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure. J Hypertens 1993; 11(suppl 3): S69-S71.
4. Brunner HR, Nussberger J, Waeber B. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system. J Hypertens 1993; 11(suppl 3): S53-S58.
5. Product Information: Cozaar(R), losartan. Merck & Co. Inc: West Point, PA, 1998.
6. Sweet CS, Nelson EB. How well have animal studies with losartan predicted responses in humans? J Hypertens 1993; 11(suppl 3): S63-S67.
7. Lo MW, Goldberg MR, McCrea JB. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-649.
8. Munger MA, Furniss SM. Angiotensin II receptor blockers: novel therapy for heart failure? Pharmacotherapy 1996; 16(suppl): 59S-68S.
9. Kazierad DJ, Martin DE, Blum RA. Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers. Clin Pharmacol Ther 1997; 62: 417-425.
10. Ohtawa M, Takayama F, Saitoh K. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol 1993; 35: 290-297.
11. Karen LG, Antona JW. Losartan potassium: A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51: 820-845.
12. Shah VP, Midha KK, Dighe S, et al. Conference Report: Analytical method validation: Bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet 1991; 16: 249-255.
13. KineticaTM 2000, Version 3.0, Innaphase, User Manual, 1999.
14. FDA Guidelines. 1 July 1992 Guidelines. Bioequivalence Food and Drug Administration, Division of Bioequivalence, Office of Generic Drugs: Rockville, MD.
15. Man-Wai Lo, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995; 58: 641-649.
16. Zaidenstein R, Soback S, Gips M, et al. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit 2001; 23: 369-373.
17. Guidance For Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER), October 2000.
18. Chow CS, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies, 2nd edn. Revised and Expanded. 2000.
19. Chow CS, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. Marcel Dekker: New York, 1992.